Novartis’ generics unit won a European panel’s recommendation for its biosimilar version of AbbVie’s Humira as the Swiss drugmaker aims to take a bite out of sales of the world’s best-selling medicine.

While Seres has seen explosive headcount growth over the past year, the company is planning for more. Seres is expanding its physical footprint in Cambridge and hiring more staff.

With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been $667.5 billion in healthcare mergers and acquisitions, according to Dealogic. Next year is likely to continue a trend that started, or at least accelerated, last […]

AstraZeneca enters into agreement with Perrigo for rights to Entocort in the US Divestment  further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015   23 November 2015 AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights […]

Johnson & Johnson’s Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat the skin condition […]

Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune disorders, including multiple sclerosis (MS), ulcerative colitis, Crohn’s disease and others.   Biogen will obtain worldwide rights to MT-1303, excluding Asia. It will oversee global […]

RHEINFELDEN, Switzerland, July 9, 2015 /PRNewswire/ — Tillotts Pharma AG (“Tillotts”), part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort® (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca. Entocort is a locally-acting glucocorticosteroid, currently approved in more than 40 […]

July 9, 2015By Alex Keown, BioSpace.com Breaking News Staff AstraZeneca (AZN) struck a $215 million deal to sell global rights to its gastrointestinal drug Entocort to Swiss-based Tillotts Pharma AG, part of the Zeria Group. The deal will allow British-drugmaker AstraZeneca to fill a short-term revenue gap, caused in part older drugs in the company’s […]